Skip to content

Risk Factors and Machine Learning Model for Aminoglycines Related Acute Kidney Injury

Analysis of Risk Factors of Aminoglycines Related Acute Kidney Injury in Hospitalized Patients and Development of Machine Learning Model

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05533593
Enrollment
8000
Registered
2022-09-09
Start date
2022-07-01
Completion date
2023-10-31
Last updated
2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aminoglycoside Toxicity, Acute Kidney Injury

Keywords

Aminoglycosides, Acute kidney injury, Pharmacoepidemiology, Miss diagnosis, Risk factors, Logic regression

Brief summary

Drug-induced acute kidney injury (D-AKI) can occur after treatment with aminoglycosides. Predicting the risk of D-AKI is important for a tailored prevention and palliation strategy. There are currently no studies to construct a model for predicting the risk of D-AKI associated with aminoglycosides. Therefore, the study aimed to develop a model to predict the risk of D-AKI that could be used in clinical practice. Clinical data of inpatients treated with aminoglycosides at the First Affiliated Hospital of Shandong First Medical University from January 2018 to December 2020, were collected. The primary endpoint was D-AKI, defined according to the 2012 Global Outcomes for Kidney Disease Improvement (KDIGO). Patient clinical information, including demographic information, admission and discharge information, disease history, medication information, and laboratory tests, was obtained through an in-hospital electronic medical record system. Independent risk factors associated with D-AKI will be screened by univariate and multifactorial analyses. Covariates with significant differences (P \< 0.05) were included in logistic regression models. The models were evaluated by the area under the curve (AUC) of the receiver operating characteristic curve (ROC) obtained by ten-fold cross-validation. Future studies are needed to test the application of this model in clinical practice to determine whether D-AKI in this setting can be predicted and mitigated.

Interventions

Inpatients using aminoglycoside

Sponsors

Qianfoshan Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* All inpatients who used aminoglycosides during hospitalization * Hospital stay ≥ 48h * Age ≥18 years * There are two or more blood creatinine tests during hospitalization

Exclusion criteria

* Hospital stay \< 48h * Age \<18 years * Glomerular filtration rate (GFR) \< 30ml/min/1.73m2 within 48 hours after admission * AKI was diagnosed on admission * Less than two Scr test results during hospitalization * The Scr values were always lower than 40 μmol/L during hospitalization * Cases with incomplete medical history information

Design outcomes

Primary

MeasureTime frameDescription
The incidence of acute kidney injury in hospitalized patients treated with aminoglycosidesThrough study completion,up to half a year.To analyze the incidence of acute kidney injury in hospitalized patients after using aminoglycosides and to build a prediction model.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026